Ralph V Boccia MD

Center for Cancer and Blood Disorders

6410 Rockledge DrSuite 660Bethesda, MD 20817
Phone+1 301-571-0019
Fax+1 301-571-0988

Dr. Boccia is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Boccia's full profile Already have an account?

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1983 - 1986
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1980 - 1981
University of Minnesota Medical School

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1980 - Present
MD State Medical License 1983 - 2028
DC State Medical License 2002 - 2024
NJ State Medical License 2015 - 2019
MN State Medical License 1978 - 1986
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013, 2015-2017
CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013, 2015-2017
CMS Meaningful Use Stage 2 Certification NextGen Patient Portal, NextGen Healthcare, 2013, 2015-2017

Clinical Trials

Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients
UNKNOWN
PHASE2
A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer
COMPLETED
PHASE2
A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome
TERMINATED
PHASE2

Publications & Presentations

PubMed

Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6.
David Andorsky, Adelba Torres Lopez, Rakhee Vaidya, Fernando Vargas Madueno, Sami Ibrahimi
Clinical Lymphoma, Myeloma & Leukemia. 2026-05-01
1 citations
mRNA engineering of allogeneic mesenchymal stem cells enables coordinated delivery of T cell engagers and immunotherapeutic cues.
C Andrew Stewart, Shaji Daniel, Elizabeth J Curvino, Yi Zhang, Hafsa Kamboh
Nature Biomedical Engineering. 2026-04-01
4 citations
Effect of Ferric Carboxymaltose Versus Low-Dose Intravenous Iron Therapy and Iron Sucrose on the Total Cost of Care in Patients with Iron Deficiency Anemia: A US Claim...
Winghan Jacqueline Kwong, Kevin Wang, Peng Wang, Ralph Boccia
Drugs - Real World Outcomes. 2024-06-01

Journal Articles

Carfilzomib vs Bortezomib in Patients with Multiple Myeloma and Renal Failure: A Subgroup Analysis of ENDEAVOR
Ruben Niesvizky, David Siegel, Ralph Boccia, Blood

Abstracts/Posters

Impact of Parenteral Iron Therapy on Hemoglobin Normalization: A Retrospective Analysis
Ralph Boccia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazo...
Ralph V. Boccia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Efficacy and Safety of Ferric Carboxymaltose Injection in Reducing Anemia in Patients Receiving Chemotherapy for Non-Myeloid Malignancies: A Phase 3, Placebo-Controlle...
Ralph V. Boccia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Severe Hypophosphatemia in Patients with Cancer Following IV Iron Treatment: Results from a Large Comparative Trial
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

What to Watch for at COA’s 2026 Community Oncology ConferenceApril 27th, 2026
American Oncology Network and the Center for Cancer and Blood Disorders Welcome Dr. Chitra RajagopalOctober 7th, 2025
American Oncology Network and the Center for Cancer and Blood Disorders Welcome Dr. Garrett Diltz and Dr. Shreya DesaiAugust 7th, 2025